Objective To analyze the efficacy and influencing factors of flumatinib as second-line treatment for elderly patients with chronic myeloid leukemia in chronic phase(CML-CP).Methods A retrospective study including 25 elderly CML-CP patients who received flumatinib as a second-line drug for more than 3 months in our hospital from 2020 to 2023 was conducted,and the efficacy and influencing factors were analyzed.Results A total of 25 patients who failed first-line imatinib treatment were collected,with a median follow-up of 24(2-48)months,22(88.0％)patients obtained complete hematological response(CHR)and 10(40.0％)patients obtained major molecular response(MMR).Univariate analysis showed that Sokal score was a factor influencing patients to obtain MMR;Sokal score,duration of imatinib treatment and pretreatment resistance status were influencing factors of CCyR.The median progression-free survival(PFS)and overall survival(OS)were 19.4 months and 22.5 months,respectively.The incidence rate of hematologic adverse events was 28.0％(7/25)and the incidence rate of non-hematologic adverse events was 20.0％(5/25).Conclusions Flumatinib is safe and effective in the second-line treatment of CML-CP in the elderly.
维普
万方数据